Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Research & Development (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Research & Development for 3 consecutive years, with $28.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 26.63% to $28.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $121.0 million, a 52.05% decrease, with the full-year FY2024 number at $203.7 million, up 6.32% from a year prior.
  • Research & Development was $28.5 million for Q3 2025 at Inhibrx Biosciences, up from $22.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $82.1 million in Q4 2023 to a low of $22.3 million in Q2 2025.
  • A 3-year average of $45.7 million and a median of $38.1 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: grew 2.2% in 2024, then tumbled 67.08% in 2025.
  • Inhibrx Biosciences' Research & Development stood at $82.1 million in 2023, then crashed by 59.35% to $33.4 million in 2024, then dropped by 14.48% to $28.5 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Research & Development are $28.5 million (Q3 2025), $22.3 million (Q2 2025), and $36.9 million (Q1 2025).